Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo

about

Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo

Item

http://www.wikidata.org/entity/Q57150012

description

scientific article published on 01 September 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Engineered FVIII-expressing cy ...... c B cells in vitro and in vivo

@en

Engineered FVIII-expressing cy ...... c B cells in vitro and in vivo

@nl

type

Item

label

Engineered FVIII-expressing cy ...... c B cells in vitro and in vivo

@en

Engineered FVIII-expressing cy ...... c B cells in vitro and in vivo

@nl

prefLabel

Engineered FVIII-expressing cy ...... c B cells in vitro and in vivo

@en

Engineered FVIII-expressing cy ...... c B cells in vitro and in vivo

@nl

P1476

Engineered FVIII-expressing cy ...... c B cells in vitro and in vivo

@en

P2093

Kalpana Parvathaneni

http://www.w3.org/2001/XMLSchema#string

P2860

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

Remote control of therapeutic T cells through a small molecule-gated chimeric receptor.

Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII

Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease

An oxygen sensitive self-decision making engineered CAR T-cell.

Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses.

FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII.

Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients

Factor VIII inhibitors: a 50-year perspective.

Inhibitory antibodies in hemophilia A.

P304

2332-2340

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOODADVANCES.2018018556

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

David W Scott

P577

2018-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30232086

http://www.w3.org/2001/XMLSchema#string

P932

6156881

http://www.w3.org/2001/XMLSchema#string